Dr. Monika Rak’s research include basic and translational research in non-viral DNA/RNA delivery as well as cancer development, progression, and therapies. A majority of her work has focused on innovative lipofection systems and vaccines carriers. Additionally, she engaged in research exploring cancer cell migration, invasiveness and epigenetic therapies. Her current project topic is the role of Human Endogenous Retroviruses (HERVs) in the development and progression of glioblastoma. Research approach includes in silico, in vitro and in vivo.
ORCID identifier: https://orcid.org/0000-0003-4746-944X
Selected Publications:
-Rak M, Góra-Sochacka A, MadejaZ. Lipofection-Based Delivery of DNA Vaccines. Methods Mol Biol.2021;2183:391-404. doi: 10.1007/978-1-0716-0795-4_20. Blaine Pfeifer and AndrewHill (Eds): Vaccine Delivery Technology.
-Rak M, Ochałek A, Gawarecka K,Masnyk M, Chmielewski M, Chojnacki T, Swiezewska E, Madeja Z. Boost of serum resistance and storage stability in cationic polyprenyl-based lipofection byhelper lipids compositions. Eur J Pharm Biopharm. 2020; S0939-6411(20)30228-9.doi: 10.1016/j.ejpb.2020.07.028.
-Ramakrishnan S, Granger V, RakM, Hu Q, Attwood K, Aquila L, Krishnan N, Osiecki R, Azabdaftari G, Guru K,Chatta G, Gueron G, McNally L, Ohm J, Wang J, Woloszynska A. Inhibition of EZH2induces NK cell-mediated differentiation and death in muscle-invasive bladdercancer. Cell Death Differ. 2019 Oct;26(10):2100-2114.
-Stalinska J, Houser L, Rak M,Colley SB, Reiss K, Jursic BS. Exploring anticancer activity of structurally modified benzylphenoxyacetamide (BPA); I: Synthesis strategies and computational analyses of substituted BPA variants with high anti-glioblastoma potential. Sci Rep. 2019 Nov 19;9(1):17021.
Keywords: Gene transfer, vaccines delivery, cancer invasiveness, Human Endogenous Retroviruses (HERVs)
